HTR2A and Prader-Willi syndrome: With a typical expression of HTR2A throughout development and lower functional expression of HTR2C in PWS leading to less inhibitory effect, there is greater potential for clinical response to lower doses of SSRIs as well as adverse effects of mood activation at typical doses (Durette et al., 2012; Gourash et al., 2015).